MDSAML

a computer
Quiz
Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?
01/20/2022
According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?
According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?
According to data from a phase...
01/20/2022
Oncology
News
Aspacytarabine is Safe, Well-Tolerated for Patients With Newly Diagnosed AML
01/20/2022
Data from a phase 2b study on aspacytarabine, a prodrug of cytarabine, as a single agent for induction and consolidation therapy for patients with newly diagnosed AML who are unfit for standard induction chemotherapy, were presented at the...
Data from a phase 2b study on aspacytarabine, a prodrug of cytarabine, as a single agent for induction and consolidation therapy for patients with newly diagnosed AML who are unfit for standard induction chemotherapy, were presented at the...
Data from a phase 2b study on...
01/20/2022
Oncology
?
Test Your Knowledge
Quiz: Does This Monotherapy Induce High CR/CRi Rates in AML?
01/10/2022
True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.
True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.
True or false: Gilteritinib...
01/10/2022
Oncology
News
Gilteritinib Monotherapy Induces High Rate of Complete Response in FLT3-Mutated AML
01/10/2022
Data from the phase 2/1b sub-study of the Beat AML Master Trial were presented at the 2021 ASH Annual Meeting and assessed the efficacy of gilteritinib monotherapy with the addition of decitabine in non-responders in older newly diagnosed...
Data from the phase 2/1b sub-study of the Beat AML Master Trial were presented at the 2021 ASH Annual Meeting and assessed the efficacy of gilteritinib monotherapy with the addition of decitabine in non-responders in older newly diagnosed...
Data from the phase 2/1b...
01/10/2022
Oncology
Dr Lee
Videos
Dr Lee Highlights the Treatment Landscape for Patients With MDS, AML
11/29/2021
Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.
Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.
Sangmin Lee, MD, highlights the...
11/29/2021
Oncology
aw
Conference Insider
Exploring Dosing Regimens of Sabatolimab Therapy for MDS/AML
12/14/2020
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Study findings support further...
12/14/2020
Oncology
News
Ruxolitinib Plus Azacitidine Tolerable for Advanced Phase MPN, Post-MPN AML
12/02/2020
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Ruxolitinib combined with...
12/02/2020
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use